Actively Recruiting
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
Led by Hubei Cancer Hospital · Updated on 2024-03-15
134
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this randomized study is to investigate pneumonitis, local tumor control, and survival outcomes of primary tumor radiotherapy omitting CTV for patients with advanced NSCLC responded to immunotherapy and chemotherapy
CONDITIONS
Official Title
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed advanced non-small cell lung cancer (according to the 8th edition of the TNM cancer staging system of AJCC and UICC)
- After over two cycles of chemotherapy combined with immunotherapy, the efficacy was CR, PR or SD (with a decreasing trend)
- Age 18 to 80 years old, performance status 0-1
- Measurable or evaluable lesions
- Survival expectancy is not less than 6 months
- Adequate cardiac, pulmonary, renal, hepatic, and bone marrow function
You will not qualify if you...
- Tumor progression after therapy with immunotherapy and chemotherapy
- EGFR, ALK, or ROS1 mutation
- Previous thoracic radiotherapy
- Grade 2 or more immune-related adverse events after induction immunotherapy
- Previous malignancies except stage I non-melanoma skin cancer or cervical carcinoma in situ
- Pregnant or lactating women
- Currently participating in other clinical trials
- Serious comorbidities including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, psychosis, and uncontrolled diabetes
- HIV positive and undergoing antiviral therapy
- Active tuberculosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Actively Recruiting
Research Team
G
Guang Han, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here